Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MAP2 | P11137 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359023 | 0.84 | MAPT (0.52) | CYP3A4TSHRSMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL8812557 | 0.80 | ALDH1A1 (0.46) | CYP3A4TSHRSMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL11223797 | 0.79 | NOS2 (0.49) | TSHRSMN1; SMN2ALDH1A1CSNK2A1TP53 | |
| SCHEMBL7519140 | 0.79 | ALDH1A1 (0.44) | CYP3A4TSHRALDH1A1ALOX15TDP1 | |
| SCHEMBL9070294 | 0.79 | ALDH1A1 (0.59) | CYP3A4TSHRALDH1A1ALOX15TDP1 | |
| SCHEMBL10799484 | 0.78 | ALDH1A1 (0.53) | CYP3A4TSHRALDH1A1ALOX15TDP1 | |
| SCHEMBL1341730 | 0.78 | CYP3A4 (0.48) | CYP3A4TSHRSMN1; SMN2ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL9781178 | 0.78 | ALDH1A1 (0.57) | CYP3A4TSHRALDH1A1ALOX15TDP1 | |
| SCHEMBL25974456 | 0.78 | HTR2A (0.46) | CYP3A4TSHRSMN1; SMN2CSNK2A1MEN1 | |
| SCHEMBL29811646 | 0.77 | ALDH1A1 (0.61) | CYP3A4TSHRSMN1; SMN2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792264-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2024-01-03 | — | — | EP | disclosed |
| CN-108368114-B | Pyrrolopyrimidine compounds as MNK inhibitors | 生命弧度公司 | 2023-10-24 | — | — | CN | disclosed |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2021-04-20 | — | — | US | disclosed |
| EP-3792264-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2021-03-17 | — | — | EP | disclosed |
| EP-3792264-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2021-03-17 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-10-15 | — | — | US | disclosed |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2020-08-11 | — | — | US | disclosed |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | LIFE ARC (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20150352124-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2015-12-10 | — | — | US | disclosed |
| US-9115140-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | disclosed |
| EP-2834248-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150036-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2013-10-10 | — | — | WO | disclosed |
| US-20130261106-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2013-10-03 | — | — | US | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-6680319-B2 | TREATMENT OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA, TREATMENT OF LOWER URINARY TRACT SYMPTOMS | RECORDATI S.A. (CH) | 2004-01-20 | — | — | US | disclosed |
| US-20020161012-A1 | Isoxazolecarboxamide derivatives | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-10-31 | — | — | US | disclosed |
| US-6365591-B1 | FOR THERAPY OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA (BPH), AND IN THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND NEUROGENIC LOWER URINARY TRACT DYSFUNCTION (NLUTD) | RECORDATI, S.A., CHEMICAL AND PHARMACUETICALS COMPANY (CH) | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352124-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | CYP3A4 102/4885TSHR 1326/4885SMN1; SMN2 1959/4885 |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | NR0B1, NR2E1, HRH4 | CYP3A4 988/4885TSHR 688/4885SMN1; SMN2 400/4885 |
| US-20130261106-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | CYP3A4 41/4885TSHR 1326/4885SMN1; SMN2 2135/4885 |
| US-20020161012-A1 | Isoxazolecarboxamide derivatives | ADRA1D, NMUR1, NMUR2 | CYP3A4 1502/4885TSHR 2444/4885SMN1; SMN2 2771/4885 |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | CYP3A4 32/4885TSHR 1404/4885SMN1; SMN2 1970/4885 |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | CYP3A4 27/4885TSHR 920/4885SMN1; SMN2 2461/4885 |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | CYP3A4 24/4885TSHR 946/4885SMN1; SMN2 2323/4885 |
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | DPYD, VEGFA, FLT1 | CYP3A4 2071/4885TSHR 3529/4885SMN1; SMN2 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.